Business
Mesoblast (ASX:MSB) and Novartis to commercialise remestemcel-L for ARDS – The Market Herald
Mesoblast (ASX:MSB) has entered an exclusive licence and collaboration agreement with Novartis to commercialise Mesoblast’s remestemcel-L therapy drug.
- Stem cell researcher Mesoblast (MSB) has entered a licence and collaboration agreement with Novartis to commercialise its remestemcel-L therapy drug
- Novartis is a Swiss-based pharmaceutical company with nearly two decades of experience in delivering products to help people with respiratory issues
- The companies will initially target remestemcel-L on treating COVID-19 related and non-COVID-19 related acute respiratory distress syndrome (ARDS)
- The drug is being used in a 300-patient COVID-19 ARDS, study…
Continue Reading
-
Noosa News23 hours agoHow Lily Steele-Park took her rapist to court and won
-
Noosa News23 hours agoE-biker charged with riding dangerously, assaulting cop
-
Business16 hours agoWhy Vault Minerals, Droneshield, Westgold Resources shares are climbing higher today
-
General21 hours agoBrick portico a relic of ‘prestigious’ Horton College in northern midlands